Gene Therapy for HER-Positive Cancer (SENTRY-HER2)

This gene therapy trial (SENTRY-HER2) is testing a new treatment for people with HER2-positive cancers — cancers that have too much of a protein called HER2 on their surface. The trial has two parts: one for advanced or metastatic disease, and one for early-stage cancers at high risk of coming back. **You may be eligible if...** - You are 18 or older with a confirmed HER2-positive solid tumor - For Part 1: your cancer is advanced or metastatic and has progressed after prior treatment - For Part 2: you have early-stage HER2-positive cancer at high risk for relapse after standard or neoadjuvant treatment - Your general health score is 0 or 1 (fully active or mildly restricted) - Your heart, lungs, liver, kidneys, and blood counts are within required ranges - Your antibody levels to the gene therapy carrier (AAV capsid) are low enough **You may NOT be eligible if...** - You have active liver inflammation (elevated AST or ALT) - You have active brain or spinal fluid involvement of your cancer - You have a history of certain blood-clotting disorders or other disqualifying conditions Talk to your doctor to see if this trial is right for you.